Share

Developing a Vaccine and Identifying Therapies for COVID-19

Johnson & Johnson just announced the launch of a Phase 3 clinical trial for its COVID-19 vaccine candidate. But what does this step in the process really mean? We asked two experts whose job it is to test vaccines to help demystify the clinical trial process—step by step.

e’re committed to bringing a safe and effective vaccine to the public on a not-for-profit basis for emergency pandemic use. Through our collaborations with health leaders around the world, we are engaging diverse scientists from inside and outside our company with the goal of delivering large volumes of a safe and effective vaccine as soon as early 2021.

We’ve established a baseline understanding of the safety profile of our vaccine platform through the data from the more than 100,000 individuals that have been vaccinated in studies examining our recently approved Ebola vaccine and our investigational HIV and Zika vaccine candidates. We are building on this foundation by evaluating the safety and effectiveness of our COVID-19 vaccine candidate in a methodical, stepwise approach. We’ve initiated the phase 3 study of our COVID-19 vaccine candidate that will assess the safety and effectiveness in up to 60,000 participants, including diverse individuals disproportionately impacted by COVID-19.

We’re also working with global partners to screen a library of molecules, including antivirals, in order to identify potential treatments that could contribute to providing immediate relief to the current pandemic.

More on Our Progress & Commitment

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue